<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01657669</url>
  </required_header>
  <id_info>
    <org_study_id>GS-01-12</org_study_id>
    <nct_id>NCT01657669</nct_id>
  </id_info>
  <brief_title>Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results</brief_title>
  <official_title>Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Retina Research Institute, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Valley Retina Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Retina Research Institute, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label study to evaluate 2.0 mg intravitreal aflibercept injection&#xD;
      administered in subject who have active choroidal neovascularization due to Age Related&#xD;
      Macular Degeneration (AMD).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Twenty (20) consented participant who meet the inclusion criteria will be enrolled to be&#xD;
      followed for 48 weeks. All subjects will receive 2.0 mg intravitreal aflibercept injections&#xD;
      with three initial monthly doses, and mandatory doses at Weeks 16, 24, 32, and 40. Dosing at&#xD;
      monthly intervals is allowed if needed in the opinion of the investigator based on presence&#xD;
      of fluid on Optical Coherence Tomography (OCT) and/or a decrease in visual acuity of greater&#xD;
      than or equal to 5 letters from the best previous visit. Only one eye will be enrolled in the&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>October 2012</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Resolution time of intraretinal cysts and sub retinal fluid on OCT</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change in OCT central foveal thickness</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects with no fluid on OCT</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects who lose less than 15 letters of visual acuity</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of subjects who gain greater than or equal to 15 letters of visual acuity</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in visual acuity</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in macular volume</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative change in area (microns) from baseline in choroidal neovascular lesion characteristics/size as measured by ICG/FA/Fundus photos</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean number of injections of 2.0 mg intravitreal aflibercept injection</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Age Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Intravitreal Aflibercept injection</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mg) via intravitreal injection once every 8 weeks (2 months).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intravitreal Aflibercept injection</intervention_name>
    <description>Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection once every 8 weeks (2 months). Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of 5 letters or more from the best previous visit.</description>
    <arm_group_label>Intravitreal Aflibercept injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Ability to provide written informed consent and comply with study assessments for the full&#xD;
        duration of the study.&#xD;
&#xD;
        Age 50 years and above.&#xD;
&#xD;
        Choroidal neovascularization secondary to AMD with central retinal thickness greater than&#xD;
        or equal to 300um.&#xD;
&#xD;
        Best corrected visual acuity in the study eye between 20/40 and 20/400 using an ETDRS chart&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Pregnancy (positive urine pregnancy test) or lactation.&#xD;
&#xD;
        Premenopausal women not using adequate contraception. The following are considered&#xD;
        effective means of contraception: surgical sterilization or use of oral contraceptives,&#xD;
        barrier contraception with either a condom or diaphragm in conjunction with spermicidal&#xD;
        gel, an IUD, or contraceptive hormone implant or patch.&#xD;
&#xD;
        Participation in a study or an investigational drug or device within the past 30 days prior&#xD;
        to enrolling in the study.&#xD;
&#xD;
        Presence of significant subfoveal fibrosis or atrophy.&#xD;
&#xD;
        Previously treated subjects:&#xD;
&#xD;
        Prior treatment with anti-VEGF therapy in the study eye within 28 days of baseline More&#xD;
        than six (6) prior treatments with anti-VEGF therapy in the study eye within 1 year.&#xD;
&#xD;
        Prior treatment with PDT within the past 3 months or more than 2 prior PDT treatments.&#xD;
&#xD;
        Prior treatment with intravitreal aflibercept injection Prior treatment with triamcinolone&#xD;
        in the study eye within 6 months of baseline.&#xD;
&#xD;
        Prior treatment with dexamethasone in the study eye within 30 days prior to baseline.&#xD;
&#xD;
        Intraocular surgery (including cataract surgery)in the study eye within 2 months preceding&#xD;
        baseline&#xD;
&#xD;
        History of vitrectomy surgery, submacular surgery, or other surgical intervention for AMD&#xD;
        in the study eye.&#xD;
&#xD;
        Active intraocular inflammation (grade trace or above) in the study eye&#xD;
&#xD;
        Current vitreous hemorrhage in the study eye&#xD;
&#xD;
        History of rhegmatogenous retinal detachment or macular hole (Stage 3 or 4) in the study&#xD;
        eye.&#xD;
&#xD;
        Active infectious conjunctivitis, keratitis, scleritis, or endophthalmitis in either eye.&#xD;
&#xD;
        Uncontrolled glaucoma in the study eye (defined as IOP greater than or equal to 30 mmHg&#xD;
        despite treatment with anti-glaucoma medication)&#xD;
&#xD;
        History of cerebral vascular accident, myocardial infarction, transient ischemic attacks&#xD;
        within 3 months of study enrollment.&#xD;
&#xD;
        History of allergy to fluorescein, ICG or iodine, not amenable to treatment&#xD;
&#xD;
        History of retinal pigment epithelial tear or rip.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaurav K. Shah, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Retina Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Retina Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63128</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Retina Institute</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>August 2, 2012</study_first_submitted>
  <study_first_submitted_qc>August 3, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2012</study_first_posted>
  <last_update_submitted>October 26, 2017</last_update_submitted>
  <last_update_submitted_qc>October 26, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Retina Research Institute, LLC</investigator_affiliation>
    <investigator_full_name>Rhonda Weeks</investigator_full_name>
    <investigator_title>Gaurav K. Shah, MD, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Choroidal neovascularization due to AMD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aflibercept</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

